A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single Doses of TAK-137 in Healthy Subjects
Latest Information Update: 06 Nov 2021
At a glance
- Drugs TAK 137 (Primary)
- Indications Attention-deficit hyperactivity disorder; Neurological disorders; Psychiatric disorders
- Focus Adverse reactions
- Sponsors Takeda
- 12 Jan 2015 New trial record